APMD Apnimed, Inc.
$26.23▼ -2.13%
Healthcare
Other
After hours
$26.69▲ +1.75%
Sep 11, 7:30 PM ET
Volume 207.7K
Avg Volume (10D) 336.8K
Key Metrics & Fundamentals
Market Cap
$1.09B
P/E Ratio
4.6
Div Yield
–%
52W Range
16.12 - 35.29
% vs 50 MA
–%
% vs 200 MA
–%
RSI-14
49.8
Free Cash Flow
-$18.45M
Gross Rev
$12.08M
Gross Profit
$10.87M
EBITDA
-$97.08M
COGS
$1.21M
Operating Exp
$22.57M
Operating Income
-$11.70M
EBIT
-$11.70M
Pretax Income
$126.11M
Net Income
$125.94M
EPS (Diluted)
3.16
Price & Volume History
Loading chart…
Recent News
Apnimed Q2 Swings to Earnings, Revenue Declines
MT Newswires · Sep 8, 2026 8:52 PM

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Sep 8, 2026 8:39 PM

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 4, 2026 8:01 PM

BofA makes bullish call on newly public biotech stock
TheStreet · Aug 29, 2026 1:03 AM

Moderna Stock Carries A Market Value Its Revenue Does Not Support
Trefis · Aug 26, 2026 3:13 PM

Apnimed shares surge on bullish BofA initiation
Proactive · Aug 25, 2026 4:12 PM

Moderna Stock Had A Readout Waiting In Plain Sight
Trefis · Aug 24, 2026 7:01 PM

Moderna's Melanoma Result Landed On A Market Positioned The Other Way
Trefis · Aug 20, 2026 6:21 PM

Apnimed (APMD) Joins The NASDAQ Composite Index
Simply Wall St. · Aug 14, 2026 7:12 AM
Stock Market, IPO Leaders Rally To New Highs. Check This Screen Daily.
Investor's Business Daily · Aug 7, 2026 1:52 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See APMD's money flow as a full page
Social Sentiment
No Reddit posts found for APMD.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.